Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
yes buys are being reported as sells
Plenty of them. I am convinced of fund managers piling in. Happy to see this back up and running. Another 50% rise soon I predict. Given the low free float and demand will explode the share price. We have already seen 50%.
yup agree. the new addition in management is to get fund managers and II onboard. from todays movement I think this is just getting started here now. im sure we will see £1 in weeks which is propelled by low number of shares available.
Rex Pharma PLC (LON:REDX) has a ‘potent combination’ of assets, according to the drugs analyst at City broker Cantor Fitzgerald. Providing the backbone to Dr Brian White’s 105p a share valuation is a potentially “best in class” Porcupine inhibitor, which should undergo first-in-human studies early next year. Porcupine inhibitors are a new method of fighting the killer disease. They work by targeting cancer stems cells that can often lie dormant after traditional treatment and are associated with a recurrence of the illness. Kill the stem cells and you have a chance of eradicating the disease completely. Novartis currently is the only drug major with a Porcupine inhibitor in the clinic and Redx is using the Swiss giant’s compound as its benchmark “with a view to coming up with something better”. Cantor’s White said these Porcupine drugs could be used in combination checkpoint inhibitors to increase the potency of the cancer treatment. He added: “Cancer R&D has heavily featured the pharmaceutical industry’s continued quest to find appropriate combinations with checkpoint inhibitors and which has resulted in several high profile and valuable transactions.” The 105p net present value stands at a significant premium to the current share price of 35.6p. Also in the Redx portfolio is a next-generation of Bruton’s tyrosine kinase (BTK) inhibitors for the treatment of leukaemia. Redx’s BTK will be one of the second-generation of compounds with fewer side-effects than the market leader Imbruvica (Ibrutinib). More importantly, the company’s drug is targeted at overcoming resistance that patients have developed to ibrutinib. Redx hopes to have selected a candidate by the end of this year ready to go into the clinic in early 2018. That’s far from the end of the story for the oncology pipeline, which includes a smoothened inhibitor for basal cell carcinoma (a form of skin cancer). It is also developing a compound that inhibits IDO, a pathway active in many cancers and it is working on a number of targets in the emerging area of immuno-oncology. In anti-infectives, Redx has teamed up with the Liverpool and Broadgreen University Hospital NHS Trust to develop drugs to tackle gram-positive bacteria such as MRSA. "Critically, these are novel drug scaffolds, so they are potentially the first new class of antibiotics in a generation,” said chief executive Neil Murray in a recent interview. “One of the main reasons that we are facing such a critical shortage of antibiotics that still work is because our industry has been unable to create new classes of drugs.” Not just that, they are designed in a way to make it very difficult for the bacteria to evolve resistance. Redx also has a programme developing drugs to combat Gram-negative strains. It is already having some early success with gonorrhoea wh
looks pretty sweet to £1
and neither has it been approved by the parliament yet. It is still a controversial project.
French still needs to give the go ahead for the budget.
"Thanks for your email. With regards to market update, we are currently working hard to find business which will bring value to shareholders and the company. Although given the current market condition, there have been many companies with assets but we are assessing which brings most value. Thank you for your continuing support." Looks like a bit of wait here.
Everyone is all sold out and I'm holding on. good to see someone bring something to the chat but no voulme here since Sept 2014, nearly half year. Combination of terrible oil price and worse coat prices have hit miners and oilers hard. Not sure the recovery will be any time soon. I think there will be a negative balance sheet final results published in June 2015. All investors are protecting cash and there are plenty of asset worth business in the market with better asset than ACO. I wish I can get my money out here. I wouldn't put my money on good news here bud, GL to both of us.
nothing to see here. Still waiting news and that will take time as far as I know. Been here for a while. True this is at bargain levels but dont expect too much anytime soon. GL.
Ahahahaha. They will be rolling 10 products by Christmas. Boom!!!
investors needs talking here. Malcy was meant to give an update on this 2 weeks ago.
:)
should've bought more last week.
should've bought more last week.
nope
Aug 4 and 8th!!
anyone have any idea?
:)
lot happening in elsewhere. People are looking into KEA I presume.